

# Whole-genome sequencing for syphilis, gonorrhoea and shigella epidemiology and control

David Eyre

Robertson Fellow and Honorary Consultant in Infection


Big Data Institute, University of Oxford  
June 2019

[david.eyre@bdi.ox.ac.uk](mailto:david.eyre@bdi.ox.ac.uk)



# What can whole-genome sequencing tell us?



- Reconstruct historical transmission events at a population scale
  - When did **Syphilis** come to Europe?
- Track the spread of infections in particular populations
  - **Shigella** as a cause of colitis in MSM
- Track the spread of antibiotic resistance
  - Identifying the likely origin of cases of MDR/XDR **gonorrhoea**
- Individual transmission tracking
  - Understand local transmission networks, e.g. evidence for serosorting or associative selectivity
  - Enhanced partner notification
- Better diagnostics?





# Pathogen DNA


This DNA allows pathogens to be put into similar groups




Bacterial DNA consists of one to a few million letters of genetic code – A, C, G or T



If infection spreads between two people the DNA of the bacteria is likely to be identical or very similar



Phylogenetic tree:



# Two theories of how Syphilis came to Europe


## Columbian theory

- Brought back to Europe by Christopher Columbus' crew
- Spread to Italy by the French during the siege of Naples in 1495 (via Spanish mercenaries)

## Pre-Columbian


- Existed before - descriptions in keeping with tertiary syphilis in ancient Greece
- Skeletons consistent with congenital syphilis from Pompeii

**Can whole-genome sequencing tell us the answer?**




# Treponema pallidum: DNA capture

- First genome sequenced in 1998, but only a handful of genomes until 2016...
- Sequencing possible direct from clinical samples in primary and secondary syphilis using RNA 'baits' → allows selective capture of low concentrations of pathogen DNA



# Historical perspective


- 70 clinical samples 2012-13 and 18 historic samples from 1912 onwards



- IND1 (blue)
- AU15 (red)
- NE20 (purple)
- CZ27 (green)
- NE17 (light blue)
- Annotated repeat regions, *tpr* genes and rRNA operon (grey)

- Austria (red)
- Switzerland (yellow)
- Czech Republic (green)
- Argentina (light blue)
- USA (orange)
- Netherlands (purple)
- Mexico (pink)
- Bosnia (brown)
- Ghana (dark blue)
- Indonesia (dark purple)
- Samoa (teal)
- Guinea (magenta)

Common ancestor of modern Syphilis dates back to 17-19<sup>th</sup> century (cf. 1495 reports in Europe)



Lineages named after reference genomes

Most circulating strains worldwide are from the SS14 lineage


- Emerged 1950s to 1970s
- Most azithromycin resistant

Nichols limited mostly to N America ≤ 1980s

0.75 SNPs / genome / year

# Success of the SS14 lineage likely multifactorial


- WGS of 73 samples from UK and USA + 49 previous sequences





# Shigellosis as a sexually transmitted infection


- Outbreaks of colitis due to *Shigella flexneri* serotype 3a reported from 1970s, large UK outbreak in 2009 onwards in MSM
- *Shigella flexneri* serotype 3a from UK 2004-2013 sequenced together with isolates from 29 countries




Cases associated with isolates from Asia or travel to Asia


Cases associated with isolates from Africa or travel to Africa

No travel to high risk areas for foodborne acquisition





MSM-outbreak lineage found predominant in men without a history of recent travel; of those with data on sexuality 40/41 MSM had MSM-outbreak lineage



# Antibiotic resistance

| Associated resistances  |                           |
|---|---------------------------|
| <b>Shigella resistance locus multidrug resistance element</b> |                           |
| <i>bla</i> <sub>OXA-1</sub>                                   | β-lactams                 |
| <i>catA1</i>  | Chloramphenicol           |
| <i>aadA1</i>  | Aminoglycosides           |
| <i>tet(B)</i>   | Tetracyclines             |
| <b>pKSR100 (conjugative R-plasmid)</b>                        |                           |
| <i>erm(B)</i>   | Macrolides (erythromycin) |
| <i>mph(A)</i>   | Macrolides (azithromycin) |
| <i>bla</i> <sub>TEM</sub>                                     | β-lactams                 |
| <b>pKSR100 integron</b>                                       |                           |
| <i>dfrA17</i>   | Trimethoprim              |
| <i>sul1</i>   | Sulfonamides              |
| <i>aadA5</i>  | Aminoglycosides           |
| <b>pCERC1 (R-plasmid)</b>                                     |                           |
| <i>dfrA14</i>   | Trimethoprim              |
| <i>sul2</i>   | Sulfonamides              |
| <i>strA</i>   | Aminoglycosides           |
| <i>strB</i>   | Aminoglycosides           |

MSM=men who have sex with men.

**Table 3: Antibiotic resistance genes and associated resistances on mobile genetic elements in the MSM-associated outbreak lineage**



In all isolates

In common isolates from 2009 onward  
**Macrolide resistance** important in success of MSM-outbreak lineage

Also associated with other serotypes, e.g. 2a and *S. sonnei*




Intensified shigellosis epidemic associated with sexual transmission in men who have sex with men - *Shigella flexneri* and *S. sonnei* in England, 2004 to end of February 2015



# *Shigella sonnei*

- In 2015, *Shigella sonnei*, isolated in 4 men in London
  - Macrolide resistant, but also ESBL
- pKRS100-like plasmid found (same as *S. flexneri* 3a outbreak), with additional *bla*<sub>CTX-M-27</sub> gene
- Look back over WGS of all *S. sonnei* sent to PHE identified 9 patients within 5 SNPs, 7 identified as MSM, but no epidemiological links found between them



# Tracking XDR gonorrhoea

- March 2018 – **XDR gonorrhoea** diagnosed
  - Ceftriaxone resistant and high-level azithromycin resistance
  - UK resident heterosexual male
  - Recent sexual contact with female in Thailand
- Key **public health questions**
  - **Where did this strain come from?** → is it circulating elsewhere?
  - **How has it become resistant?**
  - What has this strain evolved from? What is its **potential to spread?**

**BBC** | Sign in

**NEWS**

**Man has 'world's worst' super-gonorrhoea**

By James Gallagher  
Health and science correspondent, BBC News

© 28 March 2018 [f](#) [m](#) [t](#) [e](#) [Share](#)



GETTY IMAGES

# How do we use WGS to identify person-to-person transmission?

- Context from previous studies: 1407 sequences obtained from Brighton from 1061 genetically distinct infections
- **How many genetic differences do we expect between recently transmitted genomes?**
  - **SNPs, single nucleotide polymorphisms**

THE LANCET  
Infectious Diseases

## Whole-genome sequencing to determine transmission of *Neisseria gonorrhoeae*: an observational study



*Dilrini De Silva\**, *Joanna Peters\**, *Kevin Cole*, *Michelle J Cole*, *Fiona Cresswell*, *Gillian Dean*, *Jayshree Dave*, *Daniel Rh Thomas*, *Kirsty Foster*, *Alison Waldram*, *Daniel J Wilson*, *Xavier Didelot*, *Yonatan H Grad*, *Derrick W Crook*, *Tim E A Peto*, *A Sarah Walker*, *John Paul†*, *David W Eyre†*

*Lancet Infect Dis* 2016;  
16: 1295–303



# Within-sample diversity:


12-14 colonies picked from 6 randomly chosen samples



**Minimal within sample diversity, a sweep of growth sequenced for remaining samples**


## Anatomical site diversity:

Opportunistic sequencing of all patients with samples from more than one site



## Transmission pairs


30 samples from 15 contact pairs



Both used together to estimate within-host diversity



# Evolutionary rates:


Very little chronic infection, so estimated from time-scaled phylogenies



# Transmission nomogram





Number of SNPs expected between isolates linked by direct or indirect transmission





**Figure 3: Proportion of Brighton gonorrhoea infections genetically linked to another sampled case**


# Evidence of mixed HIV sero-status transmission clusters



Peters *et al*, 2017, STI

500 SNPs

# Gonorrhoea in east London



Clustering seen by reported sexual orientation, but not HIV status or ethnicity

Results do not support assortative selectivity as an explanation for infection rate differences between ethnic groups

# Detecting antibiotic resistance mechanisms

- 681 samples sequenced from UK, USA, Canada, and WHO reference collections
- MICs determined by gold standard agar dilution in national surveillance
- Catalogue of common resistance determinants identified


Overall predict MIC to nearest doubling dilution 54% of assays and to within 1 doubling dilution 93% and to within 2 doubling dilutions 98%

**Table 1.** Susceptibility-modifying genetic elements.<sup>11</sup>

| Gene/element                                  | Characteristic  | Summary   | Reference        | AZM | CFX | CIP | PEN | TET |
|---|---|---|------------------|-----|-----|-----|-----|-----|
| <i>penA</i>                                   | allele  | reduced $\beta$ -lactam acetylation of PBP2   | 11,32,33         |     | ✓   |     | ✓   |     |
|   | SNPs: A311V, I312M, V316T, V316P, T483S, A501V, N512Y, G545S, A501P, A501V, A501T, G542S, P551S, P551L  | <i>penA</i> alleles were defined as described in the Methods section, and represent commonly occurring combinations of SNPs               | 11,25            |     | ✓   |     |     |     |
|   | SNPs: D345a, F504L, A510V, A516G, H541N, P551S, P551L, P552V, K555Q, I556V, I566V, N573a, A574V, A311V, I312M, V316T, V316P, T483S, A501V, N512Y, G545S, A501P, A501V, A501T, G542S, P551S, P551L | additional contributions of individual SNPs were also investigated  | 11,34            |     |     |     | ✓   |     |
| <i>mtrR</i> promoter disruption               | deletion of A in repeat (-35A)  | overexpression of MtrCDE efflux pump  | 35,36            | ✓   | ✓   |     | ✓   | ✓   |
|   | A $\rightarrow$ C in repeat (-38)<br>2 bp insertion<br>mtr120   | novel promoter for MtrCDE efflux pump expression  | 6,37<br>36<br>38 |     |     |     | ✓   | ✓   |
| <i>mtrR</i>                                   | A39T  | overexpression of MtrCDE efflux pump  | 39               | ✓   | ✓   |     | ✓   | ✓   |
|   | G45D truncation   |   | 39<br>13         |     |     |     |     |     |
| <i>penB</i> (porB1b)                          | G120K   | reduced influx  | 40               |     | ✓   |     | ✓   | ✓   |
| <i>ponA</i> ( <i>ponA1</i> allele)            | A121D/N   |   | 40               |     |     |     |     |     |
|   | L421P   | reduced $\beta$ -lactam acylation of PBP1   | 41               |     | ✓   |     | ✓   |     |
| <i>pilQ</i>                                   | E666K   | reduced influx via pore-forming secretin PilQ   | 42               |     | ✓   |     | ✓   |     |
| <i>bla<sub>TEM</sub></i>                      | <i>bla<sub>TEM</sub>-1/bla<sub>TEM</sub>-135</i> -encoding plasmids   | penicillinase   | 43,44            |     |     |     | ✓   |     |
| 23S rRNA                                      | C2611T  | four copies of these genes present, increasing resistance with increased number of copies with SNPs via decreased binding to 50S ribosome | 45               | ✓   |     |     |     |     |
|   | A2059G  |   | 46               |     |     |     |     |     |
| <i>erm(B)</i> , <i>erm(C)</i> , <i>erm(F)</i> | presence  | methylate 23S RNA to block binding  | 47               | ✓   |     |     |     |     |
| <i>macAB</i>                                  | promoter mutation   | efflux pump overexpression  | 48               | ✓   |     |     |     |     |
| <i>mef</i>                                    | presence  | efflux pump   | 49               | ✓   |     |     |     |     |
| <i>ere(A)</i> , <i>ere(B)</i>                 | presence  | macrolide esterase  | 37               | ✓   |     |     |     |     |
| <i>gyrA</i>                                   | S91F  | reduced quinolone binding to DNA gyrase   | 13,50            |     |     | ✓   |     |     |
|   | D95N/G  |   | 13,50            |     |     |     |     |     |
| <i>parC</i>                                   | D86N  | reduced quinolone binding to topoisomerase IV   | 13               |     |     | ✓   |     |     |
|   | S87R/I/W  |   | 13               |     |     |     |     |     |
|   | S88P  |   | 13,50            |     |     |     |     |     |
| <i>norM</i>                                   | E91K  |   | 13,50            |     |     |     |     |     |
|   | promoter mutation   | overexpression of efflux pump   | 51               |     |     | ✓   |     |     |
| <i>rpsJ</i>                                   | V57M  | reduced affinity of 30S ribosome for tetracycline   | 52               |     |     |     |     | ✓   |
| <i>tetM</i> plasmid                           | Dutch/American plasmid  | TetM resembles elongation factor G, binds 30S ribotype and prevents tetracycline binding  | 53,54            |     |     |     |     | ✓   |



# UK XDR case vs. previous ceftriaxone resistant cases



# What about resistance?

Ceftriaxone resistance from the most successful *penA* gene variant to date, azithromycin from the most common high-level resistance mutation

| Gene        | Variant                                  | Mechanism   | Antimicrobials affected |
|-------------|--|---|-------------------------|
| 23S rRNA    | A2059G, 4 copies                         | Decreased macrolide binding to 50S ribosome                             | AZM                     |
| <i>penA</i> | FC428 mosaic <i>penA</i> - 100% identity | Reduced $\beta$ -lactam acylation of penicillin binding protein (PBP) 2 | CRO, PEN                |
| <i>penB</i> | G120K, A121D                             | Reduced influx through PorB1b   | CRO, PEN, TET           |
| <i>mtrR</i> | G45D, Promoter deletion                  | Over-expression of MtrCDE efflux pump resulting in increased efflux     | AZM, CRO, PEN, TET      |
| <i>ponA</i> | L421P                                    | Reduced $\beta$ -lactam acylation of PBP1                               | PEN                     |
| <i>tetM</i> | Gene presence                            | Prevents tetracycline binding to the 30S ribosome                       | TET                     |
| <i>rpsJ</i> | V57M                                     | Reduced affinity of 30S ribosome for tetracycline                       | TET                     |
| <i>gyrA</i> | S91F, D95A                               | Reduced quinolone binding to DNA gyrase                                 | CIP                     |
| <i>parC</i> | S87R                                     | Reduced quinolone binding to topoisomerase IV                           | CIP                     |

AZM: azithromycin; CIP: ciprofloxacin; CRO: ceftriaxone; PEN: benzylpenicillin; TET: tetracycline.




Comparing the UK isolate to all 7,812 sequences available for *N. gonorrhoeae*

- Rapid search to find 100 most closely related
- Precision tree for these 100



A further development...




The image is a screenshot of the ABC News website. At the top, there is a black navigation bar with a hamburger menu icon and the word "Sites" on the left, and the ABC logo on the right. Below this is a dark grey header with the "NEWS" logo in large white letters. Underneath the header is a horizontal menu with categories: "Just In", "Politics", "World", "Business", "Sport", "Science", "Health", "Arts", and "Analysis". Below the menu is a row of social media sharing buttons: "Print", "Email", "Facebook", "Twitter", and "More". The main content area features a large, bold headline: "UK man's super-gonorrhoea cured — but now two Australians have it". Below the headline, it says "Updated 21 Apr 2018, 4:47am".



Two Australian residents

- A male who reported sexual contact with a female in South East Asia
- A female who had no travel history outside of Australia

Both had ceftriaxone-resistant gonorrhoea with high-level azithromycin resistance



# European transmission of ceftriaxone resistant gonorrhoea October – December 2018

- Two female patients developed gonorrhoea following contact with UK-resident men from the same sexual network linked to travel to Ibiza, Spain
- Ceftriaxone resistant, intermediate susceptible to azithromycin

**Both cases were genetically identical – suggesting recent common source**



# Potential impacts

- Able to confirm likely transmission of ceftriaxone resistant gonorrhoea in Europe → public health response and raised public awareness
- Data from all cases from the FC428 clone suggest South East Asia or China, is the likely reservoir → need for enhanced surveillance in region
- Highlights the need for multifactorial interventions – new drugs, ?vaccine, access to diagnostics, surveillance, test of cure, effective partner notification



# What about sequencing as a routine diagnostic tool?




- Potential to
  - Detect presence of infection
  - Detect antibiotic resistance determinants
  - Enhance partner notification

# Leeds real-time sequencing study

- Illumina based sequencing of positive cultures
- Investigate the utility of WGS for routine use alongside partner notification
- Aiming to return final report based by 14 day test of cure visit


**WGS enables links to be made between cases not revealed by existing partner notification**

- Cluster of 6 MSM
- 4 are identical isolates
- Only one link made on the basis of partner notification




## WGS suggest the presence of unsampled common sources

Cluster containing 3 verified couples and 3 heterosexual females without matches




# Direct from sample sequencing



# Direct from sample sequencing

ONT sequencing direct from a patient urine sample:  
Urine sample A



Proof of principle:  
Resistance  
determinants  
identified within 8-12  
hours

# Conclusions

- Whole-genome sequencing can inform about historical and recent transmission events at a global and national scale
- Whole-genome sequencing can identify antibiotic resistant determinants and track their spread
- There is a challenge to know how best to use whole-genome sequencing in the clinic
  - It may be very helpful to identify antibiotic resistance
  - Genomic links allow the reach of partner notification to be potentially quantified
  - Active question about how to approach genomically linked cases not linked by routine partner notification

# Acknowledgements

## GU Medicine, Oxford

- Emily Lord, Natasha Regisford-Reimmer, Anne Edwards

## Microbiology, Oxford

- Monique Andersson, Markus Morgan, Robert Newnham

## University of Oxford

- Teresa Street, Nicholas Sanderson, Kevin Chau, Leanne Barker, Derrick Crook, Tim Peto

## PHE

- Gwenda Hughes, Nick Phin  
Michelle Cole, Helen Fifer



Public Health  
England

## WHO coordinating centre

- Daniel Golparian, Magnus Unemo

Oxford University Hospitals   
NHS Foundation Trust



## Australia

- Amy Jennison, David Whiley, Monica Lahra

## London

- Jayshree Dave



## Brighton

- John Paul, Jo Peters, Keven Cole



## Leeds

- Ling Yuan Kong, Mark Wilcox, Ines Moura
- Janet Wilson and rest of GU medicine team



UNIVERSITY OF LEEDS

